Evidence supporting the use of: Polyunsaturated fatty acid
For the health condition: Chronic Obstructive Pulmonary Disorder

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Polyunsaturated fatty acids (PUFAs), particularly omega-3 fatty acids, have been investigated for their potential benefits in patients with Chronic Obstructive Pulmonary Disease (COPD). The rationale stems from their recognized anti-inflammatory properties, as chronic inflammation is a central feature of COPD pathophysiology. Several observational studies have reported that higher dietary intake of omega-3 PUFAs is associated with reduced risk of COPD exacerbations and improved lung function. Additionally, small randomized controlled trials have evaluated supplementation with fish oil (rich in EPA and DHA), finding modest improvements in some markers of inflammation and, in a few cases, slight improvements in exercise capacity and quality of life. However, the evidence is inconsistent, with some studies showing no significant clinical benefit. Major reviews and guidelines, such as those from the Global Initiative for Chronic Obstructive Lung Disease (GOLD), do not currently recommend PUFA supplementation as standard therapy for COPD due to limited and mixed results. In summary, while there is a scientific basis for the use of PUFAs in COPD and some preliminary positive findings, the overall quality and consistency of the evidence are not strong, meriting a moderate-low rating of 2 out of 5 for evidence strength.

More about Polyunsaturated fatty acid
More about Chronic Obstructive Pulmonary Disorder

Products containing Polyunsaturated fatty acid

We currently have no products on Vitabase that contain this ingredient.